USPTO Examiner PETRITSCH AMANDA MICHELLE - Art Unit 1612

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18886244Oral Care Compositions Comprising Monodentate And Polydentate LigandSeptember 2024June 2025Allow920YesNo
18382761CYCLOPENTANONE COMPOUNDSOctober 2023December 2024Allow1310NoNo
18368190FORMULATIONS OF CLOMAZONESeptember 2023April 2025Abandon1910NoNo
18446041VACCINE ADJUVANTS BASED ON TLR RECEPTOR LIGANDSAugust 2023January 2024Allow510NoNo
18311704GOLD AND PALMITOYL PENTAPEPTIDE-4 NANOPARTICLESMay 2023April 2025Allow2421NoNo
18295907USE OF APE1/REF-1 INHIBITORS FOR TREATMENT OF RETINAL DISEASESApril 2023March 2025Allow2310NoNo
18115340MINERAL TREATMENT METHOD FOR DAMAGED TEETHFebruary 2023May 2023Allow300NoNo
18088448Peroxymonosulfate Oral Whitening CompositionsDecember 2022October 2024Allow2120NoYes
18083133MOISTURIZER COMPOSITIONS AND METHODS OF MAKING THE SAMEDecember 2022March 2024Abandon1510NoNo
18074608PERSONAL CARE COMPOSITIONS FOR CLEANSING THE SKINDecember 2022April 2025Allow2831YesNo
17961785Oral CompositionsOctober 2022April 2025Allow3020YesNo
17949833Sulfate-Free Surfactant SystemSeptember 2022June 2024Allow2110NoNo
17944550Jammed Emulsion Toothpaste CompositionsSeptember 2022June 2025Allow3340NoNo
17942390TISSUE STAIN AND USE THEREOFSeptember 2022January 2025Allow2821NoNo
17880300APPARATUS, METHODS AND SYSTEMS FOR LOW ENERGY PROCESSING OF CONSUMER PERSONAL HYGIENE PRODUCTS; FORMULATIONS OF THE SAMEAugust 2022November 2024Abandon2711NoNo
17877907USE OF CANNABINOID COMPOUNDS IN ORAL CARE COMPOSITIONS TO INHIBIT THE GROWTH OF P. GINGIVALISJuly 2022December 2023Abandon1701NoNo
17813636AGRICULTURAL PESTICIDE COMPOSITIONSJuly 2022July 2024Allow2320YesNo
17661276USE OF CANNABINOIDS IN THE TREATMENT OF ORAL INFLAMMATION AND PERIODONTAL DISEASEApril 2022December 2023Abandon2001NoNo
17720164DENTAL WHITENING COMPOSITIONApril 2022December 2023Abandon2010NoNo
17656646ORAL CARE PRODUCT WITH CANNABINOID COMPOUNDSMarch 2022December 2023Abandon2101NoNo
17683687OPIOID INDEPENDENT SURGICAL ANESTHETICMarch 2022May 2025Allow3931NoNo
17648612Dental Composition Comprising Potassium Nitrate and PropolisJanuary 2022April 2024Abandon2720NoNo
17628715COMPLETE FOOD FOR AQUACULTURE ANIMALS FORMED FROM INSECT LARVAEJanuary 2022March 2025Abandon3701NoNo
17550935SERIAL FILTRATION TO GENERATE SMALL CHOLESTEROL-CONTAINING LIPOSOMESDecember 2021March 2025Allow3920YesNo
17541835COMPOSITION HAVING EXCELLENT PHYSICAL PROPERTIES, BIOSTABILITY, AND EFFECTS OF REDUCING BACTERIAL ADHESION AND BIOFILM FORMATION AND OF AMPLIFYING SOD ACTIVITY, FOR ORTHODONTIC CORRECTION AND PREVENTION AND TREATMENT OF DENTAL DISEASESDecember 2021September 2023Abandon2110NoNo
17614548USE OF MAGNESIUM HYDRIDE IN PREPARATION OF COMPOSITION FOR PREVENTING AND TREATING CHRONIC PERIODONTITIS, AND MAGNESIUM HYDRIDE TOOTHPASTENovember 2021August 2024Allow3301NoNo
17610258CONTROLLED RELEASE DEVICE FOR ORAL CAVITYNovember 2021April 2025Abandon4110NoNo
17452216COSMETIC MICRONEEDLEOctober 2021October 2024Abandon3620NoNo
17497301NHAP CONTAINING ORAL COMPOSITIONOctober 2021August 2023Allow2211YesNo
17490377INFLAMMATION REDUCING COMPOSITION CONTAINING A CANNABIS SATIVA COMPOUNDSeptember 2021June 2023Abandon2010NoNo
17482721Oral Care Substance Delivery Device and Method of ManufactureSeptember 2021June 2023Abandon2001NoNo
17471888DISSOLVABLE SOLID ARTICLE CONTAINING ANTI-BACTERIAL ACTIVESSeptember 2021September 2023Allow2520YesNo
17468858Graffiti Removal SystemSeptember 2021April 2023Allow1910NoNo
17404754TEETH CLEANING AND REMINERALIZING TOOTHPASTESAugust 2021April 2024Abandon3220YesNo
17399000INK FORMULATION AND MANUFACTURE THEREOFAugust 2021December 2024Abandon4021NoNo
17383934Oral Care Compositions Containing Sodium Lauroyl Sarcosinate and BetaineJuly 2021September 2024Allow3830YesNo
17372373BRANCHED AMINO ACID SURFACTANTS FOR PERSONAL CARE AND COSMETIC PRODUCTSJuly 2021November 2024Allow4041NoNo
17359026Oral Care CompositionsJune 2021July 2023Allow2420NoNo
17417305COMPOSITION FOR ORAL CAVITYJune 2021June 2023Allow2420NoNo
17303780ORAL CARE PRODUCT FORMULATIONJune 2021September 2022Allow1600NoNo
17308081Oral Care Compositions Comprising Monodentate And Polydentate LigandMay 2021February 2025Abandon4530NoNo
17245330Mouthwash For Oral Care BenefitsApril 2021June 2024Allow3840NoNo
17245179Oral Powder Mixture With Small Sized ParticlesApril 2021January 2025Allow4560NoNo
17287560FOAMABLE DENTAL CARE COMPOSITION, SYSTEM CONSISTING OF THE DENTAL CARE COMPOSITION AND A DISPENSER, AND USE OF THE DENTAL CARE COMPOSITION IN A METHOD FOR SIMULTANEOUSLY CLEANING SEVERAL, PREFERABLY ALL, TEETHApril 2021November 2023Abandon3111NoNo
17234241REMINERALIZATION OF TEETH USING BRAZILIAN GREEN PROPOLISApril 2021January 2023Allow2010YesNo
17286390COSMETIC TENSIONING COMPOSITIONApril 2021January 2025Abandon4550NoNo
17273661GLASS COMPOSITIONMarch 2021April 2024Allow3830NoNo
17172103ABSORBABLE BONE WAX HAVING FUNCTION OF PROMOTING BONE REPAIR AND PREPARATION METHOD THEREOFFebruary 2021September 2024Allow4320NoNo
17267806A biphasic hydrogel formulation and methods of production and use thereofFebruary 2021May 2024Abandon4001NoNo
17264877SUNSCREEN COMPOSITION, USE OF THE SUNSCREEN COMPOSITION AND PROCESS OF MANUFACTURING THE SUNSCREEN COMPOSITIONFebruary 2021June 2023Abandon2820NoNo
17146935METHODS AND COMPOSITIONS FOR FLUID DRAINAGE BY PIEZO ION CHANNEL ACTIVATIONJanuary 2021August 2024Allow4330NoNo
17251009FOAMING COMPOSITIONDecember 2020August 2024Allow4540NoNo
17251108METHOD FOR APPLYING FALSE EYELASHES AND MAKEUP METHODDecember 2020July 2023Allow3120NoNo
16972465NOVEL SELF-ASSEMBLED AMINO ACID SUPRAMOLECULAR POLYMER, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOFDecember 2020August 2022Allow2111NoNo
16972461SELF-ASSEMBLED AMINO ACID SUPRAMOLECULAR POLYMER, PREPARATION THEREFOR, AND APPLICATION THEREOFDecember 2020September 2022Allow2111YesNo
15734687CYCLOPENTANONE COMPOUNDSDecember 2020August 2023Allow3330YesNo
17105748Antimicrobial Dental GelNovember 2020June 2023Abandon3000NoNo
17072318SULFATE-FREE SURFACTANT SYSTEMOctober 2020July 2022Allow2100NoNo
17067650Fluoride-free Oral Care CompositionOctober 2020January 2023Abandon2710YesNo
17046504Disintegrating Oral Tablet Suitable For Active Pharmaceutical IngredientsOctober 2020January 2025Abandon5150NoNo
17039185Tablet Dosage Form For Buccal Absorption Of Active IngredientsOctober 2020August 2024Allow4740NoNo
17042500GOLD AND PALMITOYL PENTAPEPTIDE-4 NANOPARTICLESSeptember 2020May 2023Abandon3221NoNo
17042606WATER-IN-OIL EMULSION COSMETICSeptember 2020July 2023Allow3330YesNo
17040143USE OF A DRY FILM FOR COSMETIC TOPICAL APPLICATIONSSeptember 2020August 2024Allow4740YesNo
17026671USE OF APE1/REF-1 INHIBITORS FOR TREATMENT OF RETINAL DISEASESSeptember 2020January 2023Allow2720YesNo
17005452COSMETIC COMPOSITION AND ITS USE, DERMOCOSMETIC FORMULATIONAugust 2020August 2022Allow2410NoNo
17003765ANTIMICROBIAL GALLIUM COMPOUNDS AND METHODSAugust 2020November 2022Allow2710YesNo
16996119APPARATUS, METHODS AND SYSTEMS FOR LOW ENERGY PROCESSING OF CONSUMER PERSONAL HYGIENE PRODUCTS; FORMULATIONS OF THE SAMEAugust 2020August 2022Abandon2411NoNo
16768459COSMETIC COMPOSITION FOR IMMEDIATE WRINKLE IMPROVEMENT AND ELASTICITY ENHANCEMENTMay 2020October 2022Abandon2811NoNo
16617272AQUEOUS MICROEMULSIONNovember 2019July 2022Allow3221NoNo
16600066METHOD FOR PRODUCING DISINTEGRATING PARTICULATE COMPOSITION COMPRISING ACID-TYPE CARBOXYMETHYLCELLULOSE, DISINTEGRATING PARTICULATE COMPOSITION COMPRISING ACID-TYPE CARBOXYMETHYLCELLULOSE, AND ORALLY DISINTEGRATING TABLET INCLUDING DISINTEGRATING PARTICULATE COMPOSITION COMPRISING ACID-TYPE CARBOXYMETHYLCELLULOSEOctober 2019April 2024Allow5461YesNo
16319673COSMETIC PRODUCT INCLUDING COSMETIC CONTAINER USING SPECIFIC RUBBERJanuary 2019June 2022Abandon4101NoNo
16099808AQUEOUS AGRICULTURAL COMPOSITION HAVING IMPROVED SPRAY DRIFT PERFORMANCENovember 2018April 2022Allow4131NoNo
16080823BONE MARROW-, RETICULOENDOTHELIAL SYSTEM-, AND/OR LYMPH NODE-TARGETED RADIOLABELED LIPOSOMES AND METHODS OF THEIR DIAGNOSTIC AND THERAPEUTIC USEAugust 2018December 2022Allow5141YesYes
16077008WATER-IN-OIL MICROEMULSIONS FOR PERSONAL CAREAugust 2018December 2021Allow4041YesNo
15764366POLYMER CONJUGATE VACCINESMarch 2018June 2022Allow5142NoNo
15736865INJECTABLE PHARMACEUTICAL FORMULATIONS OF LEFAMULINDecember 2017June 2024Allow6061YesYes
15572746OIL-IN-WATER TYPE EMULSION COMPOSITION AND METHOD FOR PRODUCING SAMENovember 2017December 2022Abandon6051NoNo
15690178TISSUE STAIN AND USE THEREOFAugust 2017August 2022Allow6051NoNo
15414771AGRICULTURAL PESTICIDE COMPOSITIONSJanuary 2017April 2022Allow6051NoNo
14912546METHOD FOR PRODUCING MICROPARTICLESFebruary 2016November 2022Abandon6071NoNo
15004338FORMULATIONS OF CLOMAZONEJanuary 2016May 2018Abandon28100NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PETRITSCH, AMANDA MICHELLE.

Strategic Value of Filing an Appeal

Total Appeal Filings
3
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
3
(100.0%)
Filing Benefit Percentile
0.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PETRITSCH, AMANDA MICHELLE - Prosecution Strategy Guide

Executive Summary

Examiner PETRITSCH, AMANDA MICHELLE works in Art Unit 1612 and has examined 81 patent applications in our dataset. With an allowance rate of 61.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner PETRITSCH, AMANDA MICHELLE's allowance rate of 61.7% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PETRITSCH, AMANDA MICHELLE receive 2.26 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PETRITSCH, AMANDA MICHELLE is 30 months. This places the examiner in the 39% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +37.5% benefit to allowance rate for applications examined by PETRITSCH, AMANDA MICHELLE. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.7% of applications are subsequently allowed. This success rate is in the 31% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 25.9% of cases where such amendments are filed. This entry rate is in the 27% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 106.7% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.